CD274 and triple-negative breast carcinoma: Several trials contributed to the approval of anti-PD1/PDL1 as first-/second-line treatment for various types of advanced cancers (e.g., hepatocellular cancer, head and neck squamous cell cancer, and triple-negative breast cancer) (22, 26, 103–105).